Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Klocker Eva Valentina |
Präsentationen bei wissenschaftlichen und nicht-wissenschaftlichen Veranstaltungen
Balic, M; Klocker, EV; Dobrić, N; Graf, R; Pancheri, L; Suppan, C; Jost, PJ; Heitzer, E; Dandachi, N
High-sensitivity detection and broad genomic profiling in HR+/HER2- breast cancer: Final comparative results using targeted single-gene and broad-panel sequencing assays.
The Journal of Liquid Biopsy Supplement: November 2024. 2024; 5(100190):-6th Annual Congress of Liquid Biopsy: “Advancing and Accelerating Access of Liquid Biopsy” (ISLB 2024); NOV 23-25, 2024; Denver, Colorado, USA.
[Poster]
FullText
Dobrić, N; Dandachi, N; Klocker, EV; Suppan, C; Graf, R; Hasenleithner, S; Jost, PJ; Heitzer, E; Balic, M
Comparison of ctDNA profiles from HR+/HER2-low and HR+/HER2-0 advanced breast cancer patients.
Proceedings of the 13th International Symposium on Circulating Nucleic Acids in Plasma and Serum (CNAPS). 2024; -13th International Symposium on Circulating Nucleic Acids in Plasma and Serum (CNAPS); MAR 4-6, 2024; Graz, AUSTRIA.
[Poster]
Dobrić, N; Dandachi, N; Klocker, EV; Suppan, C; Graf, R; Hasenleithner, S; Jost, PJ; Heitzer, E; Balic, M
ctDNA profiling of HR+/HER2-low and HR+/HER2-0 metastatic breast cancer patients.
Molecular Oncology Supplement: EACR 2024: Innovative Cancer Science. 2024; 18(S1):i-ii.-EACR 2024 Congress: Innovative Cancer Science; JUN 10-13, 2024; Rotterdam, THE NETHERLANDS.
[Poster]
FullText
Klocker, EV; Dobrić, N; Suppan, C; Graf, R; Foldi, J; Heitzer, E; Oesterreich, S; Lee, AV; Jost, PJ; Dandachi, N; Balic, M
Comparison of lobular vs NST hormone receptor-positive
metastatic breast cancer patients in early lines of treatment via
comprehensive genomic profiling and whole-genome sequencing of
circulating tumor DNA.
Proceedings of the San Antonio Breast Cancer Symposium 2024; Abstract Number: SESS-1277
. 2024; -San Antonio Breast Cancer Symposium 2024; DEC 10-13, 2024; San Antonio, TX; USA.
[Poster]
FullText
Buono, G; Deleuze A; Klocker, EV; Nardin, S; Eiriz IF; Luz, PJC; Braga, S; Harbeck, N; Dieras, VC
237P - Real-world safety and efficacy of Trastuzumab-Deruxtecan (T-DXd) in HER2-positive advanced breast cancer (ABC) elderly patients (pts): the TREX-Old retrospective registry
Session Poster viewing and lunch. 2023; Annals of Oncology(8):101223-101223.-ESMO Breast Cancer Congress; MAY 11-13, 2023; Berlin, Germany.
Dandachi, N; Graf, R; Pancheri, L; Dobric, N; Klocker, EV; Suppan, C; Jost, PJ; Heitzer, E; Balic, M
Sensitive detection of circulating tumor DNA using targeted capture sequencing in advanced HR+/HER2- breast cancer patients.
6th ACTC - Advances in Circulating Tumor Cells Book of Abstracts. 2023; -6th ACTC - Advances in Circulating Tumor Cells; SEP 20-23, 2023; Skiathos, GREECE.
[Poster]
FullText
Dandachi, N; Graf, R; Pancheri, L; Dobric, N; Klocker, EV; Suppan, C; Jost, PJ; Heitzer, E; Balic, M
A head-to-head comparison for detecting PIK3CA mutations in circulating tumor DNA of advanced HR+/HER2-breast cancer patients
ANN ONCOL. 2023; 34: S1162-S1163.-Annual Meeting of the European-Society-for-Medical-Oncology (ESMO); OCT 20-24, 2023; Madrid, SPAIN.
Doi: 10.1016/j.annonc.2023.09.1289
[Poster]
Web of Science
FullText
FullText_MUG
Dobric, N; Dandachi, N; Klocker, EV; Suppan, C; Graf, R; Hasenleithner, S; Jost, PJ; Heitzer, E; Balic, M
Comparison of ctDNA profiles from HR+/HER2-low and HR+/HER2-0 advanced breast cancer patients
ANN ONCOL. 2023; 34: S387-S387.-Annual Meeting of the European-Society-for-Medical-Oncology (ESMO); OCT 20-24, 2023; Madrid, SPAIN.
Doi: 10.1016/j.annonc.2023.09.667
[Poster]
Web of Science
FullText
FullText_MUG
Dobric, N; Dandachi, N; Klocker, EV; Suppan, C; Graf, R; Hasenleithner, S; Jost, PJ; Heitzer, E; Balic, M.
Comparison of ctDNA fraction and mutational profiles of plasma samples of HR+/HER2-low and HR+/HER2-0 advanced breast cancer patients
6th ACTC - Advances in Circulating Tumor Cells Book of Abstracts. 2023; -6th ACTC - Advances in Circulating Tumor Cells; SEP 20-23, 2023; Skiathos, GREECE.
[Poster]
FullText
Klocker, EV; Posch, F; Suppan, C; Mischitz, N; Dengler, L; Steiner, D; Müller, HD; Jost, P; Dandachi, N; Balic, M
Histopathological features and prognosis of early lobular breast cancer
Oncology Research and Treatment, Vol. 44, Suppl. 2, 2021. 2021; -Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie ; OCT 1-4, 2021; Berlin, GERMANY.
[Poster]
Suppan, C; Zhou, Q; Jahn, S; Graf, R; Klocker, EV; Terbuch, A; Kashofer, K; Posch, F; Gerritsmann, H; Dandachi, N; Heitzer, E; Balic, M
Comparison of liquid biopsy and tissue based detection of PIK3CAmutations in HR positive metastatic breast cancer patients
CANCER RES. 2021; 81(4):
[Poster]
Web of Science
Barth, DA; Brenner, C; Riedl, JM;Prinz, F; Klocker, EV; Schlick, K; Kornprat, P; Lackner, K; Stöger, H; Stotz, M;Gerger, A; Pichler, M
External validation of the prognostic relevance of the Advanced Lung Cancer Infammation Index (ALI) in pancreatic cancer patients
Proceedings of the Annual Meeting of the Austrian Society of Haematology and Medical Oncology 2020. 2020; 13 (Suppl 2): 23-65.-Annual Meeting of the Austrian Society of Haematology and Medical Oncology; MAR 19-21, 2020; Vienna, AUSTRIA.
[Poster]
Christoph Suppan, Qing Zhou, Stephan Jahn, Ricarda Graf, Eva Valentina Klocker, Angelika Terbuch, Karl Kashofer, Florian Posch, Hanno Gerritsmann, Nadia Dandachi, Ellen Heitzer, Marija Balic
Comparison of liquid biopsy and tissue based detection ofPIK3CAmutations in HR positive metastatic breast cancer patients.
SABCS 2020. 2020; -SABCS 2020; DEC 8-11, 2020; SAN ANTONIO, TEXAS, USA.
[Poster]
Suppan, C; Steiner, D; Klocker, VE; Posch, F; Henzinger, EC; Stoeger, H; Dandachi, N; Balic, M
Safety and clinical evaluation of dual inhibition with pertuzumab and trastuzumab in HER-2-positive breast cancer patients.
J CLIN ONCOL. 2020; 38(15):
[Onlinepräsentation]
Web of Science
FullText
Klocker, EV; Stotz, M; Posch, F; Stojakovic, T; Stoeger, H; Kornprat, P; Gerger, A; Pichler, M
A high AST/ALT (De Ritis)-Ratio represents a poor prognostic factor in a large cohort of patients with pancreatic cancer.
OeGHO Frühjahrstagung 2018; APR 19-21, 2018; Villach, AUSTRIA. 2018.
[Poster]